Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This review discusses the known effects of medications for benign prostatic hyperplasia on sexual function and mechanisms of dysfunction but reports no new clinical results.

This review discusses various chromatographic methods for analyzing finasteride in biological fluids and provides no clinical findings, focusing on detection techniques for different concentration levels.

Finasteride interacts with terazosin, but not doxazosin; caution needed.

This study found that six weeks of finasteride therapy before TURP reduced intraoperative blood loss and improved early postoperative quality of life in patients with benign prostatic hyperplasia.

This review summarizes key characteristics of men's health issues such as erectile dysfunction and prostate cancer, along with specific nursing considerations, and reports no new research results.

Green algae can break down finasteride, reducing environmental harm.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This study found that combining D-004 with finasteride results in more significant prevention of testosterone-induced prostate enlargement in rats compared to using either treatment alone.

This study observed no association between androgenetic alopecia and benign prostatic hyperplasia in men aged 20 and older, although a positive family history was linked to early onset of hair loss.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

This review describes techniques to manage intraoperative floppy iris syndrome linked to alpha-1 blocker use in cataract surgery, highlighting the need for patient disclosure of medication use but reports no new clinical results.

This review found that women with idiopathic hirsutism may have increased 5α-reductase activity, as indicated by elevated levels of a dihydrotestosterone-reduced metabolite, but more research is needed to confirm its clinical relevance as a biomarker.

This study found that finasteride treatment decreased VEGF expression in the prostate tissue of patients with benign prostatic hyperplasia, although it did not affect vascular density or serum VEGF levels.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

Minoxidil effectively lowers blood pressure and initially increases plasma renin activity without raising aldosterone levels.

In this study, topical application of Tectona grandis seed extracts on albino mice significantly accelerated hair growth initiation time and increased the percentage of hair follicles in the anagenic phase compared to the standard minoxidil treatment.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This review discusses dietary manipulation strategies in a mouse model of CBS deficiency and reports no new results; the authors emphasize the importance of understanding gene-diet interactions.

This study identified 26 bioactive compounds in the ethanol extract of Indigofera tinctoria leaves, which are linked to various therapeutic activities, supporting its traditional medicinal use in treating numerous health conditions.

This study supports the idea that angiolymphoid hyperplasia with eosinophilia is an inflammatory process linked to immunologic injuries rather than a proliferative condition.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This study found that among eleven tested polymethoxyflavones, 5-hydroxy-7,4′-dimethoxyflavone was the strongest steroid 5α-reductase inhibitor and suggests potential use for benign prostatic hyperplasia treatment.

This study successfully developed and validated a reverse-phase HPLC method for accurately determining finasteride and tamsulosin simultaneously in bulk and pharmaceutical formulations.

This study found that in male rats, hesperidin co-administration ameliorated finasteride-induced testicular toxicity by reducing oxidative stress and improving antioxidant status, sperm parameters, and enzyme activity compared to finasteride treatment alone.

This study developed two sensitive chromatographic methods for determining finasteride and tamsulosin hydrochloride in pharmaceutical forms, validated against International Conference on Harmonisation guidelines.

This study found that BOTOX doses of 75–100 U effectively reduce postvoiding residual urine and detrusor pressure in patients with detrusor sphincter dyssynergia.